This study uses a new AAV-F capsid to treat a mouse model of pyruvate dehydrogenase complex deficiency, achieving improved survival and disease pathology with a dose ten times lower than the standard AAV9 approach. These findings highlight its strong potential for treating this severe neurodegenerative disorder
